Behcet's Disease Market Segmentation:
Treatment Segment Analysis
The corticosteroids segment in the behcet's disease market is estimated to gain the largest revenue share of about 55% in the year 2035. Corticosteroids are potent anti-inflammatory drugs that help in reducing the inflammation associated with Behçet's disease. They are available as topical steroids and oral steroids depending on the symptom to be treated. For instance, A report published in 2021 states that a survey was conducted which resulted in the frequently used medications in Behcet’s Disease are glucocorticoids (67.6%) and colchicine (55.0%). Middle Eastern countries commonly use corticosteroids to reduce inflammation caused by Behcet’s disease.
Route of Administration Segment Analysis
The oral segment in the behcet's disease market is estimated to gain a significant share of about ~62% by end of 2035. Minimizing the inflammation caused by the disease is the main goal of the treatment and the medications used come in the form of tablets, capsules, or injections. Azathioprine, Ciclosporin, and Tacrolimus are immunosuppressants taken orally to reduce pain & infection. As most of medications for Behcet's disease are consumed orally, this is anticipated to fuel the growth of this segment and drive overall market growth throughout the course of the forecast year.
Our in-depth analysis of the market includes the following segments:
|
Treatment |
|
|
Route of Administration |
|
|
Distribution Channel |
|
